Order Article Reprints

Pacenta HL, Allen-Rhoades W, Langenau D, Houghton PJ, Keller C, Heske CM, Deel MD, Linardic CM, Shern JF, Stewart E, et al. Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Journal of Clinical Medicine. 2021; 10(7):1416. https://doi.org/10.3390/jcm10071416

Pacenta, Holly L., Wendy Allen-Rhoades, David Langenau, Peter J. Houghton, Charles Keller, Christine M. Heske, Michael D. Deel, Corinne M. Linardic, Jack F. Shern, Elizabeth Stewart, and et al. 2021. "Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force" Journal of Clinical Medicine 10, no. 7: 1416. https://doi.org/10.3390/jcm10071416

Pacenta, H. L., Allen-Rhoades, W., Langenau, D., Houghton, P. J., Keller, C., Heske, C. M., Deel, M. D., Linardic, C. M., Shern, J. F., Stewart, E., Turpin, B., Harrison, D. J., Khan, J., Mascarenhas, L., Skapek, S. X., Meyer, W. H., Hawkins, D. S., Chen, E. Y., Amatruda, J. F., ... Laetsch, T. W. (2021). Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force. Journal of Clinical Medicine, 10(7), 1416. https://doi.org/10.3390/jcm10071416